Valitacell's services include antibody titer, fluorescence polarisation, and clone selection, helping clients develop innovative medicines faster, cheaper, and with greater regulatory confidence. Their biotechnology allows for faster and cheaper manufacturing of bio-therapeutic drugs, enabling users to select cells with regulatory confidence early in the drug development process. Valitacell's analytical products and technologies support the biopharmaceutical and healthcare industries, including solutions like Quantum, ChemStress, and CellAi. Founded in 2014 and based in Dublin, Ireland, Valitacell was acquired by Beckman Coulter in September 2022.